A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer

M. J. Morris, M. A. Eisenberger, R. Pili, S. R. Denmeade, D. Rathkopf, S. F. Slovin, J. Farrelly, J. J. Chudow, M. Vincent, H. I. Scher, M. A. Carducci

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Background: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in progressive castration-resistant prostate cancer. Patients and methods: Twenty-nine patients were administered infusions of AGS-PSCA (1-40 mg/kg) every 3 weeks for 12 weeks; 18 final patients received a 40-mg/kg loading dose followed by 20-mg/kg repeat doses. Primary end points were safety and PK. Immunogenicity, antitumor activity and circulating tumor cells were also evaluated. Results: No drug-related serious adverse events were noted. Dose escalation stopped before reaching the maximum tolerated dose as target concentrations were achieved. Drug levels accumulated linearly with dose and the mean terminal half-life was 2-3 weeks across dose levels. The 40-mg/kg loading dose followed by repeated 20-mg/kg doses yielded serum drug concentrations above the projected minimum therapeutic threshold after two to three doses without excessive drug accumulation or toxicity. Significant antitumor effects were not seen. Conclusions: A 40-mg/kg loading dose followed by 20-mg/kg infusions every 3 weeks is the recommended phase II dose of AGS-PSCA. PSCA is a promising drug target and studies in prostate and other relevant solid tumors are planned.

Original languageEnglish (US)
Pages (from-to)2714-2719
Number of pages6
JournalAnnals of Oncology
Issue number10
StatePublished - Oct 2012
Externally publishedYes


  • Prostate cancer
  • Prostate stem cell antigen
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this